Original ArticleHigher long-term adherence to statins in rural patients at high atherosclerotic risk
Introduction
An established cardiovascular health disparity exists between rural and urban patients among many developed countries worldwide. Compared to their urban counterparts, rural patients have higher rates of cardiovascular mortality1 and inferior access to guideline-based care.2 Optimal medical therapy in these patients includes statins, and patient adherence is paramount for their substantial therapeutic benefit to be realized. Despite this, adherence to statins is known to be suboptimal and nonadherence confers a greater risk of recurrent myocardial infarction (MI)3 and mortality.4 Whether rural patients have poorer long-term adherence to statins is unknown. Studies comparing adherence rates in different regional settings have focused on other drug classes and have noted conflicting results. A pooled analysis of 3 studies5 found no difference between adherence to antihypertensive medications in rural and urban patients. In contrast, a large study6 in Canadian patients observed significantly greater adherence to multiple antihypertensive drug classes in rural patients. We therefore sought to determine (1) rates of long-term adherence to statins in patients with atherosclerotic cardiovascular disease (ASCVD) and (2) whether any regional differences exist and are predictive of adherence.
Section snippets
Patient cohort
Patients were identified from the Biomarkers of Atherosclerosis, Vascular, and Endothelial Dysfunction in Heart Disease (BRAVEHEART) study. The BRAVEHEART study is a prospective cohort study that recruited patients presenting for coronary angiography/percutaneous intervention (CA/PCI) to St Vincent's Hospital, Melbourne, between May 2009 and May 2013. Patients with the following were excluded: acute or chronic infections, systemic inflammatory conditions, recent or untreated malignancies, and
Baseline characteristics
The baseline characteristics of the patients are listed in Table 1. Five hundred twenty-five patients (69% male, mean age 64 ± 11 years) from the BRAVEHEART registry were contacted after a mean follow-up duration of 5.3 ± 0.9 years. Each RA was well represented with 34% of patients living in RA1, 45% in RA2, and 21% in RA3 (Fig. 2). Approximately 73% of patients had hypertension, 78% had dyslipidemia, 29% had diabetes mellitus, and 62% had a history of smoking. A substantial burden of ASCVD was
Discussion
Statins are considered a cornerstone of optimal medical therapy for patients at high ASCVD risk, and adherence is associated with reduced morbidity and mortality. In this prospective study in high-risk patients, 83% of patients overall were adherent to statins at a mean follow-up of 5.3 years. We observed that statin adherence increased in a stepwise manner with rurality, and living in outer regional areas independently predicted greater adherence. Our study is unique in that it assessed
Conclusion
Among high-risk ASCVD patients, adherence increased with remoteness, with patients living in outer regional areas reporting the greatest adherence rates. Living in a rural setting was a strong independent predictor of greater adherence; however, despite this, all-cause mortality was greater in rural areas. Living in a rural setting is not an impediment to adherence. However, other factors such as poorer access to health services, delayed diagnosis and management of ASCVD risk factors, cancers
Acknowledgments
Conflict of interests: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding sources: Associate Professor Andrew M. Wilson is supported by grants from the National Heart Foundation of Australia, Australia and Diabetes Australia Research Trust, Australia. Dr Arul Baradi is supported by Australian Government Research Training Program and Centre of Research Excellence in Cardiovascular Outcomes Improvement
References (35)
- et al.
Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario
Am J Med
(2010) - et al.
Long-term adherence with cardiovascular drug regimens
Am Heart J
(2006) - et al.
Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease
Am Heart J
(2008) - et al.
Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education
J Clin Lipidol
(2013) - et al.
Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users
J Clin Lipidol
(2012) - et al.
Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis
Can J Cardiol
(2012) - et al.
Rurality and event-free survival in patients with heart failure
Heart Lung
(2010) - et al.
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study
Am Heart J
(2015) - et al.
The Burden of Disease and Injury in Australia 2003
(2007) - et al.
Management of heart conditions in older rural and urban Australian women
Intern Med J
(2011)
Cardiovascular morbidity associated with nonadherence to statin therapy
Pharmacotherapy
Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction
JAMA
Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis
BMC Public Health
Australian Bureau of Statistics Census Geography Paper 03/01 - ASGC remoteness classification - purpose and use 2003
Self-reported use of guideline-recommended medication 12 months after acute coronary syndrome: a national longitudinal study
Eur Heart J
Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome
Clin Cardiol
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients
Am J Med
Cited by (1)
Depression and cardiovascular disease
2021, Current Opinion in Lipidology